{"id":271,"date":"2023-11-07T10:00:00","date_gmt":"2023-11-07T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=271"},"modified":"2025-09-09T07:29:05","modified_gmt":"2025-09-09T07:29:05","slug":"china-bd-2023-biotheus-and-biontech-enters-the-license-on-pd-l1-vegf-a-bsabs-pm8002-bnt327","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/271.html","title":{"rendered":"[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1\/VEGF-A BsAbs PM8002 (BNT327)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2023-11-06 (November 6, 2023)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: PM8002 (BNT327)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Zhuhai Biotheus Inc  (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): BioNTech<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: BsAbs (Bispecific antibody)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: PD-L1 and VEGF-A<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: advanced solid tumors<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage:Phase 2 studies in\u00a0China<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority: <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Under the agreement of 2023,<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">whereas Biotheus retains the rights to exploit PM8002 in\u00a0Greater China.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Biotheus will receive:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of\u00a0$55 million, <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory and sales milestone payments potentially totalling over\u00a0$1 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tiered royalties on potential future product sales. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.prnewswire.com\/news-releases\/biotheus-enters-into-strategic-partnership-with-biontech-to-develop-and-commercialize-bispecific-antibody-candidate-targeting-pd-l1-and-vegf-in-multiple-solid-tumor-indications-301978246.html\">Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications (prnewswire.com)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of Biotheus, \u666e\u7c73\u65af<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-11-06 (November 6, 2023) Asset Name: PM8002 (BNT327) Licensor (Seller): Zhuhai Biotheus Inc (China) &hellip; <a title=\"[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1\/VEGF-A BsAbs PM8002 (BNT327)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/271.html\"><span class=\"screen-reader-text\">[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1\/VEGF-A BsAbs PM8002 (BNT327)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-271","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=271"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/271\/revisions"}],"predecessor-version":[{"id":272,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/271\/revisions\/272"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}